Syndax Pharmaceuticals, Inc. (SNDX)
19.57
-0.08
(-0.41%)
USD |
NASDAQ |
Aug 24, 16:00
19.70
+0.13
(+0.66%)
After-Hours: 20:00
Syndax Pharmaceuticals EPS Diluted (Quarterly) : -0.5547 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.5547 |
| March 31, 2026 | -0.4835 |
| December 31, 2025 | -0.7786 |
| September 30, 2025 | -0.7009 |
| June 30, 2025 | -0.8322 |
| March 31, 2025 | -0.9846 |
| December 31, 2024 | -1.098 |
| September 30, 2024 | -0.9847 |
| June 30, 2024 | -0.7982 |
| March 31, 2024 | -0.8496 |
| December 31, 2023 | -0.9993 |
| September 30, 2023 | -0.7322 |
| June 30, 2023 | -0.6407 |
| March 31, 2023 | -0.5923 |
| December 31, 2022 | -0.6202 |
| September 30, 2022 | -0.5835 |
| June 30, 2022 | -0.6246 |
| March 31, 2022 | -0.6302 |
| December 31, 2021 | 1.844 |
| September 30, 2021 | -0.3972 |
| June 30, 2021 | -0.444 |
| March 31, 2021 | -0.5383 |
| December 31, 2020 | -0.4434 |
| September 30, 2020 | -0.4628 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.4202 |
| March 31, 2020 | -0.5576 |
| December 31, 2019 | -0.4425 |
| September 30, 2019 | -0.4056 |
| June 30, 2019 | -0.472 |
| March 31, 2019 | -0.5292 |
| December 31, 2018 | -0.7028 |
| September 30, 2018 | -0.6807 |
| June 30, 2018 | -0.74 |
| March 31, 2018 | -0.79 |
| December 31, 2017 | -0.80 |
| September 30, 2017 | -0.68 |
| June 30, 2017 | -0.70 |
| March 31, 2017 | -0.71 |
| December 31, 2016 | -0.59 |
| September 30, 2016 | -0.84 |
| June 30, 2016 | -0.47 |
| March 31, 2016 | -2.85 |
| September 30, 2014 | -149.63 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | -0.04 |
| December 31, 2013 | -0.03 |
| September 30, 2013 | 0.00 |
| March 31, 2013 | -0.03 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Viking Therapeutics, Inc. | -1.101 |
| Kura Oncology, Inc. | -0.769 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -49.36M |
| Revenue (Quarterly) | 72.79M |
| Total Expenses (Quarterly) | 122.15M |
| Enterprise Value | 1.786B |
| Gross Profit Margin (Quarterly) | 95.59% |
| Profit Margin (Quarterly) | -67.82% |
| Earnings Yield | -12.87% |
| Normalized Earnings Yield | -12.87 |